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Summary 
The Shwartzman reaction is elicited by two injections of lipopolysaccharide (LPS) in mice. The 
priming LPS injection is given in the footpad, whereas the lethal LPS challenge is given intravenously 
24 h later. The injection of interferon 3, (IFN-'y) or interleukin 12 (IL-12) instead of the LPS 
priming injection induced the lethal reaction in mice further challenged with LPS. Antibodies 
against IFN-q/when given together with the priming agent, prevented the lethal reaction in 
mice primed with either LPS, IL-12, or IFN-3'. Antibodies against IL-12, when given together 
with the priming agent, prevented the lethal reaction in mice primed with either LPS or IL-12 
but not with IFN-% These results strongly suggest that LPS induces the release of IL-12, that 
IL-12 induces the production of IFN-% and that IFN-7 is the cytokine that primes macrophages 
and other cell types. Upon LPS challenge, the lethal Shwartzman reaction is induced by a massive 
production of inflammatory cytokines that act on the target sites already sensitized by IFN-7. 
If mixtures of TNF and IL-1 or mixtures of TNF and IFN-3' are used to challenge mice previously 
primed with IFN-7 or ILo12, mortality is induced. In the same conditions, the individual cytokines 
or a mixture of IL-1 and IFN-3' do not replace the LPS challenge. When the mice are primed 
with LPS, the combination of TNF, IL-1, and IFN-7 induced only a partial mortality incidence 
suggesting that the involvement  of other LPS-induced factors. 
B 
acterial LPS is a cell wall component of Gram-negative 
bacteria that is responsible for most of the toxic manifesta- 
tions  associated with bacterial infections.  In mice, a lethal 
shock syndrome, known as the generalized Shwartzman reac- 
tion, can be elicited by two consecutive injections  of LPS 
(for review see 1). A priming dose of LPS, injected intrader- 
mall), in the footpad (f.p.)l, is followed after 24 h by an in- 
travenous challenge injection of LPS. After this challenge in- 
jection, which is not lethal per se, the mice die within the 
following 48 h from disseminated intravascular coagulation, 
vascular occlusion,  hemorrhage, perivascular accumulation 
of leukocytes, and necrosis (2). This hypersensitivity  reac- 
tion occurs only if the time interval between these injections 
is crucially fixed at between 18 and 24 h.  There is no re- 
sponse when the intravenous challenge of LPS is given either 
earlier or later, or when the order of priming and challenge 
1 Abbreviations used in thispaper: f.p., footpad; h, human;  m, mouse;  MIF, 
macrophage inhibiting factor; R, receptor. 
injections is reversed. FinaUy, the reaction does not occur if 
both the LPS injections are intradermal or if the priming dose 
of LPS exceeds an optimum. The careful dosage and timing 
of the LPS injections and the need of specific routes of ad- 
ministration indicate that the Shwartzman reaction is elicited 
by induced endogenous factors acting in a precise time se- 
quence. IFN-'y, TNF, and IL-1 are known to be involved 
in the pathogenesis of the generalized Shwartzman reaction. 
IFN-7 seems  important during the priming phase (3), whereas 
TNF and IL-1 are thought to be the lethal effector molecules 
acting on target sites already sensitized by IFN-% The local 
injection of LPS presumably induces the release of IFN-% 
which activates macrophages  to produce large amounts of 
TNF and ILol (4, 5). In addition, endothelial cells activated 
by IFN-% TNF, and IL-1, enhance their adherence proper- 
ties to leukocytes and their capacity to release procoagulant 
and proinflammatory factors (5). It is not clear how LPS stimu- 
lates the release of IFN-7, since the IFN-"/-producing cells, 
namely NK and T lymphocytes, are poorly responsive to LPS 
(6). Recently, a novel cytokine, IL-12, was characterized (7, 
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rophages,  induces  the production  of IFN-T in  T  and NK 
cells and initiates the differentiation of Th cells into the Thl 
lineage (for review see 9). As Gram-negative bacteria can stimu- 
late the production of IL-12 and induce a Thl response (10), 
IL-12 could be the link between the injection  of LPS and 
the endogenous production of IFN-T that sensitizes mice to 
further contact with LPS.  This study reports that  IL-12 is 
the pivotal factor in the priming phase of the Shwartzman 
reaction.  The activity of IL-12 is mediated through  the in- 
duction of IFN-%  and IFN-y or IL-1 can synergize with 
TNF-a  to elicit the lethal  reaction. 
Materials and Methods 
Mice.  NMIL[ female mice, 20-23 g body weight, were pur- 
chased from Biological Research Laboratory  (Fullingsdorf,  Swit- 
zerland)  and maintained  in our animal facilities under specit%d 
pathogen  free conditions. 
LPS.  Serratia  marcescens LPS (Sigma Chemical Co., St. Louis, 
MO) was dissolved in pyrogen-free saline to 10 mg/ml, sterilized 
by 0.22 ~m filtration,  aliquoted,  and stored frozen at  -20~ 
Cytokines.  Recombinant  human IFN-3/(hlFN-'y) and mouse 
IFN-3' (mIFN-3/) were expressed in Escherichia coli and purified ac- 
cording to Gray and Goeddel (11, 12) and Doebeli et al. (13). They 
display a specific antiviral activity of 8  x  107 U/rag and 1.2  x 
10  v U/rag of protein,  respectively. The recombinant  hlbl  (3  x 
108 U/rag of protein),  and miD12 (6.3  x  106 U/mg of protein) 
were produced by Roche Research Center (Nutley, NJ) (14-16). 
Recombinant  hTNF-c~ was expressed in E. coli and kindly provided 
by Dr.  B. Wipf and Dr.  U. Ettlin  (F. I-Ioffman La Roche Ltd., 
Basel, Switzerland). hTNF-ce  binds to the mouse p55 TNF receptor 
(17). Recombinant  hIL-6 (108 U/rag  of protein)  was from  Dr. 
DiPadova (Sandoz, Basel, Switzerland). 
Antibodies.  Pat mAbs XMG1,2  and AN18 are IgG1 against 
mIFN-y (18, 19). Pat mAb GR20 (20) is an IgG2a specific for 
mIFN-  T receptor  (mIFN-TR).  The mouse mAb 3,73 and mAb 
~/IL99 are IgG1 directed against hIFN-3, and hlFN-'yR, respectively 
(21, 22). The mAb 20C2 is a rat IgG1 neutralizing hIL-12 activity, 
whereas the rat mAbs 5C3 and C15.6.7 neutralize mIb12 activity 
(23, 24). Goat IgG anti-mIb12 and control goat IgG were pro- 
duced at Roche Research Center (Nutley, NJ) (25). Irrelevant mouse 
and rat  IgG were from Sigma Chemical  Co. 
Endotoxin Contamination.  All reagents were checked for endo- 
toxin contamination  by the Limulus amoebocyte lysate assay given 
that 1 IU/ml is equal to 0.1 ng/ml of United States Pharmacopea 
standard E. coli endotoxin (26). All the antibodies, mIb12, mIFN-% 
and  hIL-1 contained  <0.05  IU/mg protein,  hTNF-c~ contained 
12 IU/mg protein  (0.06 IU for 5 ~tg TNF-cr 
Induction of the Generalized Shwartzman Reaction in Mice.  The 
generalized Shwartzman reaction was elicited by two consecutive 
injections ofS. marcescens  LPS (1). The priming injection was given 
in the f.p. and was followed 24 h later by a challenge LPS injection 
given intravenously. The optimal  doses of LPS were determined 
for each batch of LPS and ranged between I and 5 #g for the f.p. 
injection and between 200 and 400 #g for the intravenous injec- 
tion. When the reaction was elicited with cytokines, the priming 
injection was given intraperitoneally  unless otherwise  stated, the 
challenge injection was given intravenously. In all the experiments 
described, mAbs were injected intraperitoneally. Each experimental 
group includes from three to five mice. The occurrence of the gener- 
alized Shwartzman  reaction  was evaluated by mortality scores. 
Statistical Analysis.  Differences between the treatment  groups 
was evaluated with student's  t test. 
Results 
Induction of the Generalized Shwartzman  Reaction in Mice. 
Groups of five NMRI mice received two consecutive injec- 
tions of LPS. The priming  injection was given in the f.p. 
and was followed 24 h later by the intravenous challenge in- 
jection. The reaction was lethal only if the mice received both 
the preparative and the challenge injections (87-100% mor- 
tality).  A  single f.p.  or  a single intravenous  injection was 
ineffective. 
Priming of the Mice~Replacement of  LPS with IFN-%  The 
role of IFN-3' in the pathogenesis of the Shwartzman  reac- 
tion was investigated by replacing the priming LPS f.p.  in- 
jection by IFN-3' (Table  1, Fig.  1). All the mice primed in- 
traperitoneally with  106 U  mlFN-T  (83/~g) died after the 
intravenous injection of LPS given 24 h later.  The priming 
effect was dose dependent.  In a representative experiment, 
65 and 30% lethality were induced after priming with  10  s 
U  and  104 U  mlFN-%  respectively (Fig.  1).  The priming 
effect of mlFN-3, was abrogated by boiling the protein (not 
shown) and was not due to an intrinsic  toxicity of the cytokine 
(two injections of 106 U  at 24-h intervals were ineffective, 
see Table 4). Control animals, primed with hlFN-% all sur- 
vived the LPS challenge (data not shown). These results show 
that  IFN-y  can  replace  LPS  in  priming  the  mice  to  the 
Shwartzman  reaction. 
Priming of the Mice~Replacement of  LPS with IL-12.  Since 
IL-12 induces the secretion of IFN-%  we assessed  the hy- 
pothesis that IL-12 can mimic the LPS priming effect. Table 
I displays the results of the experiments where either the LPS 
priming f.p. injection or the LPS intravenous challenge in- 
jection were replaced by raiL-12.  When mice were primed 
with 10 ng raiL-12 and challenged 24 h later with LPS, 85% 
died (Fig.  1). This priming effect ofmlL-12 was dose depen- 
dent (17 and 0% mortality for 1 and 0.1 ng mlL-12, respec- 
tively) and was abrogated by boiling the protein (data not 
shown).  The lethality was not due to an intrinsic  toxicity 
of the cytokine. A single injection of 25 #g mlL-12 or two 
consecutive injections of raiL-12 with a 24-h time interval 
were ineffective (see Table 4). These results show that miL- 
l2 can replace the LPS priming in the Shwartzman reaction 
and that mlL-12 is 1,000 times more efficient than mlFN-y 
in priming  mice (Table  1,  Fig.  1). 
Antibodies against IFN-  T Inhibit the Shwartzman Reaction when 
the Mice Are Primed with LPS, IFN-% or IL-12.  The roles 
of IFN-T and IL-12 in the pathogenesis of the Shwartzman's 
reaction were further investigated using a mAb (XMG1,2) 
that neutralizes mlFN-T activity (Table 2). A dose of 10 #g 
mAb XMG1,2 rescued mice from the shock reaction when 
given intraperitoneally simultaneously with the priming LPS 
injection (mortality reduced to 10%). Irrelevant rat IgG, mAb 
3/73 anti-human  IFN-T or mAb 3'R99 anti-human  IFN- 
TR were not effective (Table 2).  These results were further 
confirmed using AN18, another mAb anti-IFN-3/(data  not 
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Priming f.p.  Priming intraperitoneaUy  LPS challenge  No. of  No. of mice 
0 h  0 h  intravenously 24 h  experiments  dead/tested  Mortality 
LPS  5 #g 
mlFN-y  6  x  103 U 
mlFN-3'  6  x  104 U 
mlFN-y  1.2  x  105 U 
mlL-12  1 ng 
mlL-12  10 ng 
m 
LPS 
mIFN  -3, 
mlFN-'y 
mlFN-'y 
mlL-12 
mlL-12 
% 
+  1  0/5  0 
+  2  6/10  60 
5/~g  +  1  0/5  0 
+  1  0/5  0 
+  2  0/10  0 
+  1  3/5  60 
6  x  103 U  +  1  0/5  0 
6  x  104 U  +  2  6/10  60 
1.2  x  IO  s U  +  1  2/5  40 
+  1  0/5  0 
+  2  10/10  100 
1  ng  +  1  0/5  0 
10 ng  +  2  7/10  70 
For priming, raiL-12 and mlFN-3, can be injected either intraperitoneally  or in the f.p. 
shown) or GtL20 a mAb raised against the mlFN-'y (Table 
2). The antibodies to IFN-y inhibited more efficiently the 
lethal reaction than antibodies to IFN-3,R. The dosages giving 
50% protection were 1 and 30/zg for XMG-1,2 and AN18, 
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Figure  1.  Comparison  of the efficiency  of mlL-12 (V3) and mlFN-~/ 
(A) to prime intraperitoneally  the mice for the induction  of the lethal 
reaction after the LPS challenge. Each treatment group consists of five 
mice and four individual  experiments  were performed. The data of a rep- 
resentative  experiment  are shown  and the results  are expressed  in percentage 
of mortality. 
respectively, whereas 200/zg of GR20 were needed to reach 
the same protection level. This difference can be explained 
by the need to block all the mlFN-~/receptors which are ubiq- 
uitously expressed. 
When the mice were primed intraperitoneally with 105 
U  mlFN-3,, 87% of the mice died after the LPS challenge 
(Fig.  2).  This lethal reaction was partially inhibited (mor- 
tality reduced to 40%) by the injection of 100/zg anti-IFN- 
"y mAb XMG-1,2 (Fig. 2 A). About 5/zg of the same mAb 
gave a complete inhibition of the lethal reaction developed 
by mice primed with 10 ng mlL-12 and challenged with LPS. 
The amount of XMG-1,2 that protects the mice primed with 
mlFN-3, is 10-20-fold higher than the amount needed to reach 
the same protection level in mice primed with LPS or miL- 
l2 (Fig. 2 A). It can be explained by the high dose of mlFN- 
7  (105 U  =  8.3/~g) that has to be used to prime the mice. 
These results suggest that both the priming effects of LPS 
and mlL-12 are mediated by mlFN-3'. 
Antibodies against IL-12 Inhibit the Schwartzman Reaction when 
the Mice Are Primed with LPS, IL-I2, but not IFN-%  When 
given simultaneously with the LPS priming injection, goat 
anti-mlL-12 inhibited the lethal reaction (Fig. 2 B). A com- 
plete protection from lethality was obtained after intraperi- 
toneal injection of 200 ~g goat anti-mlL-12. This result was 
confirmed that using mAb 5C3 recognizes the 40-kD chain 
of the raiL-12 (mortality reduced to 20%),  whereas mAb 
20C2 raised against hlL-12 was almost ineffective (Table 3). 
To confirm that the priming effect of mlL-12 is IFN-'y de- 
pendent, we assessed the capacity of anti-IL-12 antibodies 
to inhibit the lethal reaction when the mice are primed with 
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LPS  priming  Ab  treatment  LPS  challenge  Ab  treatment  No.  of  No.  of mice 
f.p.  0  h  intraperitoneally  0  h  intravenous  24  h  intraperitoneally  24  h  experiments  dead/tested  Mortality 
% 
....  2  0/10  0 
+  -  +  -  20  89/98  91 
+  3/73  100  #g  +  -  1  5/5  100 
+  7R99  200/~g  +  -  1  5/5  100 
+  Rat  Ig  200  #g  +  -  2  9/10  90 
+  XMG1,2  10  #g  +  -  19  10/95  10 
+  GR-20  200/xg  +  -  7  8/35  23 
+  -  +  yR99  200/~g  1  4/5  80 
+  -  +  XMG1,2  10  #g  8  13/44  29 
+  -  +  GR20  200  /~g  3  4/15  27 
The anti-IFN-3" or anti-IFN-3"R antibodies  given intraperitoneaUy together with the LPS f.p. injection  (0 h) or with the LPS intravenous  injection 
(24 h) prevent  the lethal reaction.  XMG1,2 is a rat anti-mlFN-3' mAb and GR-20 is a rat anti-mlFN-3"R  mAb. ")'73 is a mouse anti-hlFN-3,  mAb 
and 3,R99  is  a mouse anti-hlFN-3,R mAb. Rat  Ig is  an irrelevant  rat  IgG. 
LPS, raiL-12, or mlFN-'y (Fig. 2 B). The goat anti-raiL-12 
antibody efficiently inhibited the Shwartzman reaction when 
mice were primed with mlL-12  (IC50 ranging between 10 
and 20/~g/mouse).  When the mice were primed with 10 ~ 
U  mlFN-%  the simultaneous injection  of 200/~g of anti- 
bodies to mlL-12 only marginally reduced the mortality in- 
duced by the LPS challenge (Fig. 2 B). Altogether these results 
confirm that the priming injection of LPS induces the release 
of raiL-12  which  in  turns  stimulates  the  production  of 
mlFN-% 
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Figure  2.  Test  of the inhibitory ef~ciency of mAb XMG1,2 anti-IFN- 
3' (tl) or goat Ab anti-IL-12 (B) in the lethal Shwartzman reaction when 
given intraperitoneaUy at time 0 h together with the priming agent. Mice 
f.p. were primed with LPS (O), with 10 ng mlL-12 intraperitoneally ([3), 
or with 0.83 #g (10  s U) mlFN-3' intraperitoneally  (A) and challenged 
intravenously with LPS 24 h later. The results are expressed as the mean 
percentage  of mortality obtained  in three to ten individual experiments 
with five mice per treatment  group.  Standard errors (vertical bars) and p 
values  (*p <  0.01,  * *p <  0.001)  are indicated. 
IFN-'y But Not IL-I2 Has a Systemic Role in the Shwartzman 
Reaction.  The priming injection of LPS was efficient if the 
injection was performed in the f.p. The same dose of LPS 
injected intraperitoneally was  ineffective.  In contrast,  the 
priming  of mice with mlFN-3/or with mlL-12  was simi- 
larly efficient when given either in the f.p. or intraperitoneaUy 
(Table 1). For both cytokines, no significant difference in the 
priming dose was found when the two routes of administra- 
tion were compared. In these experiments, a priming dose 
of 10 ng mlL-12 infected in the f.p. or intraperitoneally 24 h 
before the LPS challenge, induced 100 and 70%  mortality, 
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Figure  3.  Comparison  of the inhibitory ef~ciency  of mAb XMG1,2 
anti-IFN-y (A) or goat Ab anti-II:12  (B) in the lethal Shwartzman reac- 
tion when given intraperitoneally  either  at time 0 h together  with the 
LPS priming (Q) or at time 24 h together  with the LPS intravenous chal- 
lenge (O). Data are pooled from three to eight independent experiments 
with five mice per treatment group. The results are expressed in percentage 
of mortality. 
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LPS priming  Ab  treatment  LPS challenge  Ab treatment  No.  of  No.  of mice 
f.p. 0  h  intraperitoneal 0  h  intravenous  24 h  intraperitoneal  24  h  experiments  dead/tested  Mortality 
% 
....  2  0/10  0 
+  -  +  -  4  18/20  90 
+  mIgG  200/zg  +  -  1  5/5  100 
+  rat  IgG  200 /~g  +  -  1  4/5  80 
+  goat IgG  200/~g  +  -  1  5/5  0 
+  5C3  200/~g  +  -  2  2/10  20 
+  C15.6.7  100/~g  +  -  2  0/10  0 
+  20C2  200/zg  +  -  1  4/5  80 
+  GamlL-12  200/~g  +  -  2  0/10  0 
+  -  +  goat IgG  200 ~g  1  4/5  80 
+  -  +  Gc~mlL-12  200 #g  2  8/10  80 
The antibodies anti-mlL-12 given intraperitoneally together with the LPS f.p. injection (0 h) prevent the lethal reaction. 5C3 and C15.6.7 are rat 
anti-mlL-12 mAbs, 20C2 is a mouse anti-human IL-12 mAb. GamlL-12 is a goat anti-mlL-12 polyclonal antibody, mlgG, rat Ig and goat IgG 
are irrelevant mouse, rat IgG, or goat IgG. 
respectively. When 1.2  x  105 U  (10 #g) mlFN-3/were used 
to prime mice via the f.p. or intraperitoneally,  the mortality 
induced by the LPS challenge was 60 and 40%, respectively. 
Since raiL-12 or mIFN-y effnciently primed the mice when 
given intraperitoneally,  these cytokines may play a systemic 
role in the Shwartzman reaction. We assessed this hypothesis 
by injecting goat anti-raiL-12 antibodies or anti-IFN-3/mAb 
XMG 1,2 together with the intravenous LPS challenge. When 
the  XMG1,2  antibody  was  given simultaneously  with  the 
LPS challenge  (Fig.  3 A,  Table 2),  a  significant  protection 
from lethal shock was still observed (100/zg/mouse reduced 
the mortality to 23%).  In the  same conditions,  200/~g  of 
goat anti-mlL-12 antibodies were ineffective (Fig. 3 B, Table 
3). However, neither mlFN-3' nor raiL-12 could replace the 
challenge LPS injection of the Shwartzman reaction: the mice 
that were primed with LPS and challenged intravenously 24 h 
later with 1@ U  mlFN-y or 0.1 #g raiL-12, survived (Table 
4). Since the raiL-12 priming effects are mediated by IFN-% 
these experiments confirm that mlFN-'y plays a role in the 
lethal  reaction. 
Toxicity of TNF-cr, IL-I, and IFN-y Injected Intravenously.  To 
evaluate the  role of IFN-%  IL-1, and  TNF-ol in the chal- 
lenge phase of the Shwartzman reaction,  the toxicity of the 
cytokines  was assessed after a  single intravenous  injection. 
Table  4.  Challenge with Single Cytokines in the Skwartzman Reaction 
Challenge with  cytokine  No.  of  No.  of mice 
Priming 0  h  intravenous  24 h  experiments  dead/tested  Mortality 
IL-12 
IFN-3' 
% 
LPS  IL-1  106 U  1  0/5  0 
LPS  IL-6  106 U  1  0/5  0 
LPS  IL-12  0.1  /~g  2  0/8  0 
LPS  IFN-3/  1@ U  2  0/8  0 
LPS  TNF  5 #g  2  0/6  0 
0.01  /~g  IL-12  0.1  /zg  1  0/5  0 
106 U  IFN-'y  106 U  1  0/5  0 
Mice primed with LPS and challenged intravenously with single cytokines do not develop the lethal reaction. 
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%  when injected alone, did not induce mortality (Tables 4 
and 5). The coinjection of 105 U  IL-1 and 105 U  IFN-3' was 
neither toxic. On the contrary, TNF-oe coinjected with ei- 
ther IL-1 or IFN-3' could induce mortality (Table 5). Com- 
binations of 5 /~g TNF-cr  and  104  U  IFN-3~ or IL-1 and 
combinations of 2 #g  TNF-ot and  105  U  IFN-y or IL-1 
were not toxic in normal mice.  When the three cytokines 
were coinjected (Table 6),  2/zg TNF-o~  together with 104 
IL-1 and 105 U  IFN-'y were toxic, whereas 2/~g TNF-c~ to- 
gether  with  105  IL-1  and  104  U  IFN-3,  did  not  induce 
lethality. The dosages of cytokines applied to challenge mice 
in the Shwartzman reaction were chosen according to their 
lack of toxicity as defined in the Tables 5 and 6. 
Challenge  of  Mice  with  Cytokines  after  Priming  with 
LPS.  Mice primed with LPS and challenged intravenously 
with either TNF-oe (5/~g), IL-1 (106 U), IL-6 (106 U), or 
mIFN-3/(106 U) did not die (Table 4). Neither the coinjec- 
tion of two cytokines, TNF-o~ and IL-1, TNF-c~ and mIFN-% 
or IL-1 and mlFN-% could replace the LPS challenge in LPS- 
primed mice (Fig. 4 A). The challenges with 2 #g TNF-o~, 
104 U  IL-1, and 104 U  mIFN-3, or with 1 #g TNF-ot,  10  a 
U  IL-1, and 105 U mIFN-'y induced 33% mortality in mice 
previously primed with LPS. The mortality incidence reached 
50%  in mice primed with LPS and challenged with 2/~g 
TNF-oe,  105 U  IL-1, and 104 U  mlFN-% 
These experiments show that cytokines can induce the le- 
thal Shwartzman reaction in the LPS primed mice; that at 
least TNF-oe, IL-1, and mlFN-y can elicit the reaction; and 
that other factors may be necessary to reach 100% mortality 
incidence. 
Challenge of Mice with Cytokines  after Priming  with IFN-'y 
or IL-12.  When mice were primed with 105 U mlFN-~ or 
with 10 ng mid 12 and challenged with single cytokines such 
as TNF-c~,  IL-1, IL-6, or mlFN-3',  no mortality was ob- 
served (not shown). Fig. 4 shows that the coinjection of two 
cytokines, either TNF-cr  and mlFN-3' or TNF-oe and IL-1, 
but not IL-1 and mlFN-3', can elicit the lethal reaction in 
mice primed with mlFN-y or mlL-12. The highest mor- 
tality incidence was obtained when mice primed with cyto- 
kines were challenged with TNF-a and IFN-% The intrave- 
nous injection of 5 #g TNF-a and 104 U mlFN-3' induced 
83  and 100%  mortality in mice primed with mlL-12 and 
mlFN-% respectively.  In comparison, the injection of 5 #g 
TNF-oL and 104 U IL-1 was less efficient and induced 33 and 
83%  mortality in mice primed with mlL-12 or mlFN-3,, 
respectively.  The  injection  of 2  #g  TNF-ot  and  10  s  U 
mlFN-3' was lethal only in mice primed with mlFN-3' (67% 
mortality), whereas the injection of 2 #g TNF-a and 10  s U 
IL-1 was not effective whichever the priming cytokine. 
When the three cytokines were injected to challenge the 
mice primed with mlFN-~/or mlL-12, the minimal doses 
giving high mortality incidence were either 2 #g TNF-cz, 
104  U  IL-1,  and 104 U  mlFN-3' or  1 /zg TNF-ot,  104 U 
IL-1,  and 10  s U  mlFN-y (100%  mortality in mice primed 
with mlFN-3' and 83-100% in mice primed with raiL-12). 
The decrease from 104 to 103 U  of the IL-1 present in the 
cytokine mixture injected, reduced drastically the lethality 
of the reaction (0 and 22% mortality in mice primed with 
IL-12 and IFN-y, respectively).  On the contrary, the mor- 
tality rates did not change significantly when the mlFN-3' 
present in the cytokine combination was reduced from 10  4 
to 103 U  (76 and 83% mortality in mice primed with IL-12 
and IFN-%  respectively). 
These experiments show that TNF-a when coinjected with 
IL-1 or mlFN-3' can induce the lethal Shwartzman reaction 
in the mlL-12 or mlFN-3, primed mice and that TNF-a is 
essential  for the lethality of the reaction, whereas IL-1  or 
mlFN-3' potentiate the TNF-cr effects. Finally, these experi- 
ments show that both mlL-12 and mlFN-3/are more efficient 
priming agents than LPS in the lethal Shwartzman reaction. 
Table  5.  Toxicity of TNF-,~ when Coinjected Intravenously 
with IL-1 or mlFN-T 
/zg of TNFc~ 
0  2  5  10 
Units of IL-1 
Units of IFN-3/ 
0  0  0  0  0 
104  0  nt*  0  0 
10  s  0  0  67  100 
104  0  nt  0  67 
10  s  0  0  50  nt 
Table  6.  Toxicity of TNF-cr when Coinjected Intravenously 
with IL-1 and IFN-7 
/zg of TNF-a 
0  1  2  2  2  5 
Units  of IL-1 
Units  of IFN-3' 
106  104  103  104  10  s  104 
0  0  0 
103  0  0  nt* 
104  0  0  0  50 
10  s  0  0  0  33  100  100 
The results from two individual  experiments are expressed in percent of 
mortality. In each experiment, each treatment group includes three to 
five mice. 
* Not tested. 
The results from two to six individual  experiments are expressed in per- 
cent of mortality. 
In each experiment, each treatment group includes three to five mice. 
* Not tested. 
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100] 
60 
40 
20 
B  Priming with raiL-12 
100- 
8O 
60 
I::  40 
o 
20 
C  Priming  with mlFN7 
100 
80 
60 
40 
20 
TNFa  [gg]  5  5  2  2  2  2  2  2  1 
ILl Ix 104u]  1  -  1  10  10  1  0,1  1  1 
IFN7 Ix 104U]  1  1  10  1  1  1  0.1  10 
Figure 4.  Test  of the challenge efficiency  of TNF-c~, IL-1, and mlFN-3' 
in primed mice. Mice were primed either with 5/~g LPS in the f.p. (A), 
with  10 ng mlir  intraperitoneally (B) or with  10  s U mlFN-3' in- 
traperitoneally (C). The doses  of cytokines given to challenge primed mice 
were not toxic as defined in Tables 4 and 5. Data are pooled from three 
to five independent experiments with three mice per treatment group. 
Results are expressed in percentage of mortality. 
Discussion 
IFN-%  TNF,  and IL-1  are involved in  the  generalized 
Shwartzman reaction elicited in mice. IFN-3, is the main factor 
during the priming phase while TNF and IL-1 are the lethal 
effector molecules induced by the LPS challenge (for review, 
see 1). The anti-IFN-3~  mAbs inhibited the f.p. swelling in 
mice injected locally with LPS (3)  and protected the mice 
from the lethal reaction (1). Since the monocytes and macro- 
phages appear to be the principal cells involved in mediating 
the effects of endotoxin (27, 28), it is not clear how LPS can 
stimulate T  and NK cells to release IFN-% One hypothesis 
is that LPS-stimulated macrophages produce IL-1 and IL-6, 
which in turn activate T cells to release IFN-3, (29). The rel- 
atively low incidence of lethality observed in mice primed 
with these cytokines and challenged with LPS, suggests that 
IL-1 and IL-6 are cofactors rather than triggering agents in 
the priming  of mice (data not  shown). 
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Recent data showed that LPS can activate macrophages to 
release IL-12, a cytokine that stimulates T  and NK cells to 
release IFN-~/(9). This finding supports the idea that IL-12 
may be the missing link between LPS and IFN-3' in the gener- 
alized Shwartzman  reaction.  Following the same approach 
as that used for IFN-% we conclude that IL-12 and IFN-3, 
are  both  involved  in  the  priming  phase  of  generalized 
Schwartzman reaction.  The experiments with anti-IFN-3~ and 
anti-IL-12 antibodies show that the priming effect of IL-12 
is mediated by IFN-% 
IL-12 does not contribute to the lethality of the general- 
ized Shwartzman reaction. The anti-IL-12 antibodies injected 
together with the intravenous LPS challenge do not rescue 
the primed animals and IL-12 does not replace the LPS chal- 
lenge.  On the contrary,  the LPS primed mice treated with 
anti-IFN-3/antibodies  at the time of the LPS challenge sur- 
five. However, IFN-3' does not elicit the lethal reaction when 
injected instead of the LPS challenge.  The protective effect 
of the anti-IFN-3,  antibodies is 10 times less effective than 
that observed when the same mAbs are given together with 
the LPS priming.  These results show for the first time that 
IFN-3' contributes to the lethality of the shock reaction but 
is not a lethal effector molecule. Although evidence points 
to  TNF  and  IL-1  as  the  key  cytokines  leading  to  the 
hemodynamic  and  histologic  events  of the  septic  shock 
(30-33), we never observed a lethal reaction on challenging 
the mice with either TNF-cr  (5 #g) or 106 U  IL-1 (3.3 #g) 
after the LPS priming.  The injection of TNF-c~, IL-1, and 
IFN-3' mixture can induce an intermediate lethality (33%) 
in the mice primed with LPS.  The coinjection of TNF-ol 
and IL-1 or TNF-ol and IFN-3~ induces a lethal reaction in 
mice primed with either IL-12 or IFN-%  In these condi- 
tions, IL-1 and IFN-3' are not lethal.  This confirms TNF-oe 
as the main  effector of the Shwartzman  reaction but  that 
lethality arises in the presence of either IL-1 or IFN-% These 
observations suggest that the f.p.  priming injection of LPS 
induces not only IL-12 and IFN-3' but also antiinflamma- 
tory factors.  The fact that  the priming  with  high dose of 
LPS, i.e.,  10 #g/mouse, inhibits the lethality induced by the 
LPS challenge  supports  this hypothesis (1). 
LPS activates many cell types to produce antiinflamma- 
tory factors.  LPS-activated PMN release  enzymes, radicals, 
and a bactericidal protein called BPI (bactericidal/permeability- 
increasing  protein)  (34).  This protein competes with lipo- 
polysaccharide binding protein (35) or soluble CD14 and neu- 
tralizes LPS so that it cannot activate monocyte/macrophages 
or injure  endothelial  cells  (36,  37).  Upon LPS activation, 
monocytes produce not only IL-12,  TNF-oe, and IL-1 but 
also IL-1 receptor antagonist (IL-lra),  IL-lra, IL-6 and IL-10 
(38-40). Both IL-6 and IL-lra can also antagonize the produc- 
tion and/or the activity of IL-1 (38, 41).  IL-IO inhibits the 
production of IFN-3', the proliferation of Thl cells (42) and 
downregulates several macrophage functions, including the 
secretion of IL-1, IL-6, IL-8, IL-IO, IL-12, and TNF-ol, re- 
spiratory burst and MHC class II expression (43, 44). Since 
the maximal production of IL-10 occurs 24-48 h after LPS 
activation of macrophages,  its putative inhibitory  effect in 
the Shwartzman reaction would coincide with the challenging phase.  Thus, IL-10 could interfere with the activity of the 
lethal effector cytokines. Recently, Bernhagen (45) reported 
that the in vivo injection of LPS induces the release of mac- 
rophage  inhibiting  factor  (MIF)  by  pituitary cells.  This 
cytokine is involved in the septic  shock but its role is not 
clear. Hypophysectomised mice are more sensitive to endo- 
toxin,  whereas  the coinjection of MIF and LPS enhances 
lethality. Since IL-12 and IFN-'y do not induce MIF and IL-6, 
such a negative regulatory pathway should not take place in 
mice primed by IL-12 or IFN-% Recent reports suggest that 
IL-12 and IFN-3, have opposite effects on IL-10 production. 
IFN-3, inhibits IL-10 production by monocytes (46), whereas 
increased IL-10 production was observed in mice after daily 
injection of IL-12 for 4-5 d (47), when its relevance for the 
onset of the shock reaction is questionable. 
In conclusion, our data suggest that a cascade of cytokines 
induces the generalized Shwartzman reaction. The priming 
f.p.  injection of LPS stimulates the release of IL-12 by the 
macrophages of the draining lymph nodes and activates the 
production of IFN-3' by T and/or NK cells. IFN-3/promotes 
the inflammatory  functions of macrophage-like and endothelial 
cells, and sensitizes  them to environmental stimuli. Upon 
the systemic injection of LPS, all the sensitized cells produce 
1TNF and IL-1, that together with the newly synthesized 
IFN-'y, enhance the adherence, and trigger the procoagulant 
and proinflammatory activities of these cells. Besides IL-1, 
IFN-3'  seems necessary  for the manifestation of the TNF 
lethality in the generalized Shwartzman reaction. 
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